Crenolanib – 5 mg

Brand:
Cayman
CAS:
670220-88-9
Storage:
-20
UN-No:
Non-Hazardous - /

Crenolanib is an orally bioavailable, selective inhibitor of type III tyrosine kinases with nanomolar potencies against platelet-derived growth factor receptor α (PDGFRα) and PDGFRβ and Fms-related tyrosine kinase 3 (FLT3; IC50s = 11, 3.2, and 4 nM, respectively).{30695,30696} It also inhibits medically-relevant mutant forms of these kinases, including the D842V-containing form of PDGFR and D835Y and internal tandem duplication mutations of FLT3, at nanomolar concentrations.{30695,30693,30694} Crenolanib is more than 100-fold selective for these kinases over other tyrosine and serine/threonine kinases. It is effective when used in cells and in vivo.{30695,30696,30694}  

 

Available on backorder

SKU: - Category:

Description

An orally bioavailable, selective inhibitor of PDGFRα, PDGFRβ, and FLT3 (IC50s = 11, 3.2, and 4 nM, respectively); also inhibits mutant forms of these kinases, including the D842V-containing form of PDGFR and D835Y and internal tandem duplication mutations of FLT3, at nanomolar concentrations


Formal name: 1-​[2-​[5-​[(3-​methyl-​3-​oxetanyl)​methoxy]​-​1H-​benzimidazol-​1-​yl]​-​8-​quinolinyl]​-4-​piperidinamine

Synonyms:  CP 868,596

Molecular weight: 443.5

CAS: 670220-88-9

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|PDGFR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling||Research Area|Cell Biology|Cell Signaling|Growth Factor Receptors